| Literature DB >> 24308751 |
Irene G Sia1, Seanne P Buckwalter, Kelly A Doerr, Sonia Lugos, Rebecca Kramer, Ruth Orillaza-Chi, Maria Imelda Quelapio, Thelma E Tupasi, Nancy L Wengenack.
Abstract
BACKGROUND: The Philippines has an extremely high rate of tuberculosis but little is known about M. tuberculosis genotypes and transmission dynamics in this country. The aim of this study was to determine the proportion of household contacts who develop active TB due to direct transmission from an index case in that household.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24308751 PMCID: PMC4028849 DOI: 10.1186/1471-2334-13-571
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
IS6110 Restriction fragment length polymorphism (RFLP), spoligotyping, and mycobacterial interspersed repetitive unit variable numbers of tandem repeat (MIRU-VNTR) typing patterns of isolates from index case (IC) and household contact (HC) cases from the Philippines
| | | | | | | |
| IC1 | 5–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 244336223432 | Manila | | |
| HC1 | 5–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 244336223432 | Manila | RFLP/Spoligo/MIRU | No |
| IC2 | 10–14 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223432 | Manila | | |
| HC2 | 34–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223432 | Manila | Spoligo/MIRU | No |
| IC3 | 2–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ □□□ □□□ □□■ ■■■ ■■■ ■ | 254326223432 | ND | | |
| HC3 | 2–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ □□□ □□□ □□■ ■■■ ■■■ ■ | 254326223432 | ND | RFLP/Spoligo/MIRU | No |
| IC4 | 35–11 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223422 | Manila | | |
| HC4 | 3–12 | ■■□ ■■■ ■■■ ■■■ ■□□ □■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223432 | ND | None | No |
| IC5 | 1–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223332 | Manila | | |
| HC5 | 1–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223332 | Manila | RFLP/Spoligo/MIRU | Yes |
| IC6 | 11–15 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 234326223432 | Manila | | |
| HC6.1 | 4–16 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 234326223432 | Manila | Spoligo/MIRU (IC6/HC6.1) | No |
| HC6.2 | 6–14 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 234326223432 | Manila | Spoligo/MIRU (IC6/HC6.2) | No |
| HC6.3 | 7–13 | □■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □□□ ■■■ ■■■ ■ | 253326223432 | ND | None (IC6/HC6.3) | No |
| IC7 | 19–12 | ■■□ ■■■ ■□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□■ ■■■ ■ | 254326223432 | ND | | |
| HC7.1 | 20–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223432 | Manila | MIRU (IC7/HC7.1) | No |
| HC7.2 | 18–11 | ■■□ ■■■ □■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □□■ □■■ ■■■ ■ | 274326223432 | ND | None (IC7/HC7.1) | No |
| IC8 | 12–15 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 234326223432 | Manila | | |
| HC8 | 37–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223432 | Manila | Spoligo | No |
| IC9 | 14–19 | □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □■■ ■■■ ■■■ ■ | 223325173533 | Beijing | | |
| HC9 | 14–19 | □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □□□ □■■ ■■■ ■■■ ■ | 223325173533 | Beijing | RFLP/Spoligo/MIRU | Yes |
| IC10 | 27–12 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223422 | Manila | | |
| HC10 | 27–12 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223422 | Manila | RFLP/Spoligo/MIRU | Yes |
| IC11 | 25–15 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ □□□ □□□ □□□ □□□ □□□ □□□ □ | 254326224332 | ND | | |
| HC11 | 23–12 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 254326223432 | ND | MIRU | No |
| IC12 | 32–11 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■■□ □□□ □□□ □□□ ■■□ □□□ ■■■ ■■■ ■ | 224227163221 | ND | | |
| HC12 | 28–13 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■■□ □□□ □□□ □□□ ■■□ □□□ ■■■ ■■■ ■ | 224227163321 | ND | Spoligo/MIRU | No |
| IC13 | 29–11 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 354326223422 | Manila | | |
| HC13 | 29–11 | ■■□ ■■■ ■■■ ■■■ ■■■ ■■■ ■□□ ■■■ ■■■ ■□□ □□■ □■■ ■■■ ■■■ ■ | 354326223422 | Manila | RFLP/Spoligo/MIRU | No |
RFLP = restriction fragment length polymorphism; Spoligo = spligotyping; MIRU = multiple interspersed repeating units/variable number tandem repeats; ND = not determined; IC = index case; HC = household contact patient, DST = drug susceptibility.
When known, lineage information is listed.
Drug susceptibilities of isolates from index case (IC) and household contact (HC) cases in the Philippines
| | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IC1 | R | R | R | R | R | S | S | S | S | S | S | S | S |
| HC1 | R | R | S | S | S | S | S | S | S | S | S | S | S |
| IC2 | R | R | R | R | R | R | R | S | S | S | S | S | S |
| HC2 | R | R | R | S | S | R | R | S | S | S | S | S | S |
| IC3 | R | S | R | S | S | R | R | S | S | S | S | S | S |
| HC3 | R | R | R | S | S | S | S | S | S | S | S | S | S |
| IC4 | R | R | R | S | N/A | R | S | S | S | S | R | S | S |
| HC4 | R | R | S | S | S | R | S | S | S | S | S | S | S |
| IC5 | R | R | R | R | R | R | R | S | S | S | S | S | S |
| HC5 | R | R | R | R | R | R | R | S | S | S | S | S | S |
| IC6 | R | R | R | R | R | R | R | S | S | S | R | S | S |
| HC6.1 | R | R | R | R | S | R | R | S | S | S | R | S | S |
| HC6.2 | R | R | R | R | S | R | R | S | S | S | R | S | S |
| HC6.3 | S | S | S | S | S | S | S | S | S | S | S | S | S |
| IC7 | R | S | R | R | S | R | R | S | S | S | R | S | S |
| HC7.1 | S | S | S | S | S | S | S | S | S | S | S | S | S |
| HC7.2 | S | S | S | S | S | S | S | S | S | S | S | S | S |
| IC8 | R | S | S | S | S | S | S | S | S | S | S | S | S |
| HC8 | S | S | S | S | R | S | S | S | S | S | S | S | S |
| IC9 | R | R | R | R | R | R | R | S | S | S | S | S | S |
| HC9 | R | R | R | R | R | R | R | S | S | S | S | S | S |
| IC10 | R | S | S | S | S | S | S | S | S | S | S | S | S |
| HC10 | R | S | S | S | S | S | S | S | S | S | S | S | S |
| IC11 | S | S | S | S | S | S | S | S | S | S | S | S | S |
| HC11 | R | R | R | S | S | S | S | R | S | S | R | S | S |
| IC12 | R | R | R | R | R | R | R | R | S | S | S | S | S |
| HC12 | R | R | R | R | S | R | R | R | S | S | S | S | S |
| IC13 | R | R | R | R | S | R | S | S | S | S | S | S | S |
| HC13 | R | R | R | R | S | S | S | S | S | S | S | S | S |
Susceptibilities are reported in μg/mL.
Abbreviations: INH – isoniazid, RIF – rifampin, EMB – ethambutol, PZA – pyrazinamide, STR – streptomycin, CAP – capreomycin, KAN – kanamycin, AMI – amikacin, ETH – ethionamide, CYC – cycloserine, PAS – para-aminosalicylic acid; R – resistant, S – susceptible.
With the exception of PZA, susceptibility for all drugs was performed by the 1% indirect agar proportion method. PZA susceptibility was performed on the VersaTREK (TREK Diagnostics, Cleveland, OH).
Isolate unable to grow in test medium for PZA susceptibility testing.
Patient demographics
| IC1 | 2001 | | 41 | F | | | |
| HC1 | 2001 | 0 | 22 | F | child | N | Y |
| IC2 | 2001 | | 28 | M | | | |
| HC2 | 2001 | 0 | 18 | M | sibling | N | N |
| IC3 | 2001 | | 52 | M | | | |
| HC3 | NA | NA | 22 | F | child | N | Y |
| IC4 | 2001 | | 38 | M | | | |
| HC4 | 2001 | 0 | 10 | M | child | N | N |
| IC5 | 2001 | | 42 | M | | | |
| HC5 | 2001 | 0 | 22 | M | child | Y | Y |
| IC6 | 2002 | | 17 | M | | | |
| HC6.1 | 2002 | 0 | 20 | M | sibling | N | N |
| HC6.2 | 2002 | 0 | 29 | M | sibling | N | N |
| HC6.3 | 2002 | 0 | 22 | M | sibling | N | N |
| IC7 | 2002 | | 43 | M | | | |
| HC7.1 | 2002 | 0 | 33 | F | sibling | N | N |
| HC7.2 | NA | NA | 41 | M | sibling | N | N |
| IC8 | 2001 | | 28 | F | | | |
| HC8 | 2007 | 6 | 60 | M | parent | N | N |
| IC9 | 2001 | | 19 | M | | | |
| HC9 | 2003 | 2 | 30 | M | sibling | Y | Y |
| IC10 | 2000 | | 40 | M | | | |
| HC10 | 2003 | 3 | 40 | F | sibling | Y | Y |
| IC11 | 2003 | | NA | M | | | |
| HC11 | 2004 | 1 | NA | M | NA | N | N |
| IC12 | 2003 | | 30 | F | | | |
| HC12 | 2004 | 1 | 28 | F | sibling | N | N |
| IC13 | 2003 | | 49 | M | | | |
| HC13 | 2008 | 5 | 32 | M | child | N | Y |
DST = drug susceptibility testing, NA = not available, Y = yes, N = no.
aUsing all 3 methods (spoligotyping, MIRU-VNTR and RLFP).